Segment Information (Tables)

12 Months Ended

Dec. 31, 2011

Reconciliation Of Segment Information To Total Consolidated Information


(In thousands) Year Ended December 31, 2011	Generics Segment		Specialty Segment		Corporate / Other⁽¹⁾			Consolidated
Total revenues
Third party	$	5,579,331	$	550,494	$	—		$	6,129,825
Intersegment		2,480		70,005		(72,485	)		—

Total	$	5,581,811	$	620,499	$	(72,485	)	$	6,129,825

Segment profitability	$	1,640,135	$	208,215	$	(842,901	)	$	1,005,449


(In thousands) Year Ended December 31, 2010	Generics Segment		Specialty Segment⁽²⁾		Corporate / Other⁽¹⁾			Consolidated
Total revenues
Third party	$	5,022,554	$	427,968	$	—		$	5,450,522
Intersegment		40,116		61,772		(101,888	)		—

Total	$	5,062,670	$	489,740	$	(101,888	)	$	5,450,522

Segment profitability	$	1,398,264	$	122,694	$	(799,374	)	$	721,584


(In thousands) Year Ended December 31, 2009	Generics Segment		Specialty Segment⁽²⁾		Corporate / Other⁽¹⁾			Consolidated
Total revenues
Third party	$	4,677,813	$	414,972	$	—		$	5,092,785
Intersegment		22,081		40,757		(62,838	)		—

Total	$	4,699,894	$	455,729	$	(62,838	)	$	5,092,785

Segment profitability	$	1,322,999	$	70,400	$	(870,047	)	$	523,352

⁽¹⁾

Includes certain corporate general and administrative and research and development expenses; net charges for litigation settlements; certain intercompany transactions, including eliminations; amortization of intangible assets and certain purchase accounting items; impairment charges; and other expenses not directly attributable to segments.

⁽²⁾

Intersegment sales by Specialty increased from 2009 to 2010 due to the fact that certain generic products previously sold to third parties by Specialty are now sold to Mylan subsidiaries in the North America region of the Generics Segment who, in turn, sell the products to third parties. These generic products contributed $46.8 million to total revenues of the Specialty Segment in 2009.

Net Revenues Classified Based On Therapeutic Product Categories


	Year Ended December 31,
	2011		2010		2009
(In thousands)
Allergy	$	476,990	$	343,138	$	238,050
Anti-infective Agents		1,005,278		783,738		600,807
Cardiovascular		1,037,644		967,680		866,411
Central Nervous System		1,214,046		1,248,982		1,428,142
Endocrine and Metabolic		535,383		433,341		399,620
Gastrointestinal		492,683		462,088		401,448
Respiratory Agents		250,692		248,452		288,966
Other⁽¹⁾		1,093,561		916,847		791,950

	$	6,106,277	$	5,404,266	$	5,015,394

⁽¹⁾	Other consists of numerous therapeutic classes, none of which individually exceeds 5% of consolidated net revenues.

Net Revenues Classified Based On Geographic Location Of Customers


	Year Ended December 31, 2011		Year Ended December 31, 2010		Year Ended December 31, 2009
(In thousands)
The Americas:
United States	$	3,242,985	$	2,656,532	$	2,370,975
Other Americas		226,144		188,659		157,246
Europe⁽¹⁾		1,781,184		1,790,901		1,837,427
Asia		855,964		768,174		649,746

	$	6,106,277	$	5,404,266	$	5,015,394

⁽¹⁾	Net revenues in France consisted of approximately 11%, 13% and 14% of consolidated net revenues for the years ended December 31, 2011, 2010 and 2009, respectively.

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details